# Altimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altimmune

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.altimmune.com
- Total disclosed funding: $10M
- Latest round: Series B (Jul 1, 2004)
- Investors on record: 1

## About

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics to address critical medical conditions, particularly obesity and metabolic diseases.Founded in 1997 and headquartered in Gaithersburg, US, Altimmune, Inc. specializes in developing innovative therapeutics. The company underwent a pivotal change in 2017 when Truffle Capital exited through a merger with Pharmathene, Inc. Following this, HealthCap and Novartis Venture Fund exited their stake through an IPO. The company most recently raised USD 115 mn in a Private Placement/Follow-on on July 13, 2020, bringing its total raised to USD 115 mn.Altimmune is dedicated to developing peptide-based therapeutics, primarily focusing on Pemvidutide, aimed at tackling obesity and related metabolic issues. Their products are designed for healthcare providers and pharmaceutical distributors, enhancing treatment access for patients affected by obesity-related complications.In the most recent year, 2024, Altimmune reported a revenue of USD 20,000, with an EBITDA of USD -102,934,000, indicating a significant investment in the development of its therapeutic offerings.Altimmune plans to leverage its recent funding of USD 115 mn to enhance the development and commercialization of Pemvidutide, targeting potential market launches in the United States and selected international regions by mid-2024. This growth strategy includes expanding partnerships with healthcare providers and exploring new markets to maximize its therapeutic offerings.

## Funding rounds

- Series B, Jul 1, 2004, $10M — Redmont Venture Partners

## Investors

- Redmont Venture Partners (https://capitalatlas.ai/funds/redmont-venture-partners) — Series B